---
title: "Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype"
id: "clinicaltrials-nct07190222"
canonical_url: "https://medichelpline.com/clinical-feed/clinicaltrials-nct07190222"
content_type: "clinical_feed_article"
specialty: "Critical Care"
source_name: "ClinicalTrials.gov"
source_url: "https://clinicaltrials.gov/study/NCT07190222"
doi: "NCT07190222"
published_at: "2026-03-23T12:00:00.000Z"
evidence_level: "INTERVENTIONAL Trial"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/clinicaltrials-nct07190222
- **Specialty:** [Critical Care](https://medichelpline.com/clinical-feed/critical-care.md)
- **Primary Source:** ClinicalTrials.gov
- **Source URL:** [Original Journal Publication](https://clinicaltrials.gov/study/NCT07190222)
- **DOI:** [NCT07190222](https://doi.org/NCT07190222)
- **Published At:** 2026-03-23T12:00:00.000Z
- **Evidence Rating:** INTERVENTIONAL Trial
## Executive GIST (TL;DR)
RECRUITING · INTERVENTIONAL · TREATMENT study · Chronic Obstructive Pulmonary Disease · Phase 3 · Enrollment 942 · Sponsor: Sanofi
## Clinical Analysis & Structured Key Points
Official title: A Phase 2b/Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study, to Investigate the Efficacy and Safety of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype Summary: This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. Participation to the study consists of 3 periods: * Screening period of up to 4 weeks * Randomized intervention period of approximately 48 weeks * Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks. Conditions: Chronic Obstructive Pulmonary Disease Study type: INTERVENTIONAL Primary purpose: TREATMENT Phases: PHASE3 Enrollment: 942 (ESTIMATED) Status: RECRUITING Completion: 2030-01-22 (ESTIMATED)
## Related Clinical Research

- [25-Hydroxyvitamin D Sufficiency Linked to Lower Atelectasis Prevalence in CVID Patients](https://medichelpline.com/clinical-feed/pubmed-42758666.md) (DOI: 10.12659/MSM.953313)
- [Bronchiectasis Severity Index Validation in Alpha-1 Antitrypsin Deficiency Patients](https://medichelpline.com/clinical-feed/pubmed-42758741.md) (DOI: 10.1371/journal.pone.0355956)
- [Serum Na–Cl Difference as a Noninvasive Screen for CO2 Retention in ALS](https://medichelpline.com/clinical-feed/plos-one-2-serum-na-cl-value-from-routine-blood-tests-reflects-co-2-retention-in.md)
- [On-site AASM-accredited sleep facilities and hospital outcomes for acute hypercapnic respiratory f](https://medichelpline.com/clinical-feed/medrxiv-0-on-site-aasm-accredited-sleep-facility-status-and-hospitalization-outcomes.md)
- [CMS expands ACCESS model to cover four more chronic conditions in 2027](https://medichelpline.com/clinical-feed/healthcare-dive-2-cms-to-add-more-chronic-conditions-to-access-model-in-2027.md)

## Navigation
- [← Back to Critical Care Feed](https://medichelpline.com/clinical-feed/critical-care.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.